Intracerebral administration of nivolumab and ipilimumab (CTLA-4 monoclonal antibody) was well-tolerated and associated with encouraging OS in recurrent glioblastoma patients with maximal safe resection 116. Here, CTLA4 is linked to glioblastoma.